While the standard Bacillus Calmette-Guerin (sBCG) vaccine has been in use for about 100 years and administered over 4 billion times, its clinical efficacy is debatable.
On May 2, 2024, the Serum Institute of India (SII) confirmed that it is developing a new recombinant BCG vaccine (iBCG) to enhance efficacy and address the current supply shortages.
Founded in 1966, SII, the world's largest vaccine producer, has implemented two gene modifications to improve sBCG's immunogenicity and safety, creating iBCG.
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
